Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer

Oliver F. Bathe, Ioannis G. Kaklamanos, Frederick L. Moffat, Jodeen Boggs, Dido Franceschi, Alan S. Livingstone

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

The authors sought to examine the utility of resection in conjunction with adjuvant chemotherapy for treatment of metastases from breast cancer isolated to the liver or lungs. Limitations of regional therapy were examined and potential agents for systemic therapy were reviewed. As resection of metastases is a controversial therapeutic approach, no clinical trials are available for review. Rather, evidence for a potential role for surgery rests on retrospective studies of small series of patients. Technical advances have rendered resection of liver and lung metastases safe. Long-term results as reported by other investigators support the role of metastasectomy in selected patients. The site of failure following ablation of liver metastases is usually in the liver. Following resection of lung metastases, nonpulmonary and disseminated recurrences are most common. Adjuvant therapy with docetaxel or any other agent or combination with significant activity against visceral metastases might potentiate long-term results. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalSurgical Oncology
Volume8
Issue number1
DOIs
StatePublished - Jul 1999

    Fingerprint

Keywords

  • Breast cancer
  • Cytoreduction
  • Metastasectomy
  • Resection

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this